[go: up one dir, main page]

WO2002040059A3 - Methods and compositions for inducing cell-mediated immune responses - Google Patents

Methods and compositions for inducing cell-mediated immune responses Download PDF

Info

Publication number
WO2002040059A3
WO2002040059A3 PCT/US2001/045626 US0145626W WO0240059A3 WO 2002040059 A3 WO2002040059 A3 WO 2002040059A3 US 0145626 W US0145626 W US 0145626W WO 0240059 A3 WO0240059 A3 WO 0240059A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
variant
compositions
mediated immune
undesired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/045626
Other languages
French (fr)
Other versions
WO2002040059A2 (en
Inventor
Milcho S Mincheff
Dmitri I Loukinov
Seguei Zoubak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Foundation for Biological Research Inc
Original Assignee
American Foundation for Biological Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Foundation for Biological Research Inc filed Critical American Foundation for Biological Research Inc
Priority to AU2002239441A priority Critical patent/AU2002239441A1/en
Publication of WO2002040059A2 publication Critical patent/WO2002040059A2/en
Anticipated expiration legal-status Critical
Publication of WO2002040059A3 publication Critical patent/WO2002040059A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods and compositions for treating a subject having undesired cells, e.g., tumor cells or virally infected cells. The method comprises administering a polynucleotide encoding a variant of an antigen present on the undesired cell ('target cell'), which variant is not secreted by, or expressed on the extracellular side of the cell membrane of, the cell in which it is expressed. The variant is preferably biologically inactive. The invention provides a method for inducing a cell-mediated immune response against the undesired cell without inducing a humoral immune response. In addition, the method is safe, since the absence of a biological activity of the variant prevents the occurrence of deleterious effects in the subject receiving the variant.
PCT/US2001/045626 2000-11-01 2001-11-01 Methods and compositions for inducing cell-mediated immune responses Ceased WO2002040059A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002239441A AU2002239441A1 (en) 2000-11-01 2001-11-01 Methods and compositions for inducing cell-mediated immune responses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70423200A 2000-11-01 2000-11-01
US09/704,232 2000-11-01

Publications (2)

Publication Number Publication Date
WO2002040059A2 WO2002040059A2 (en) 2002-05-23
WO2002040059A3 true WO2002040059A3 (en) 2003-09-12

Family

ID=24828637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045626 Ceased WO2002040059A2 (en) 2000-11-01 2001-11-01 Methods and compositions for inducing cell-mediated immune responses

Country Status (2)

Country Link
AU (1) AU2002239441A1 (en)
WO (1) WO2002040059A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002326961A1 (en) * 2001-10-10 2003-04-22 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
ES2559002T3 (en) 2001-10-23 2016-02-10 Psma Development Company, L.L.C. Antibodies against PSMA
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2004092216A1 (en) * 2003-04-15 2004-10-28 Trangene S.A. Carcinoembryonic antigen (cea) lacking a signal peptide, nucleic acid encoding it and fusion of cea with a t cell epitope and their use for the treatment and/or prophylaxis of cancer
US20070196346A1 (en) * 2003-08-21 2007-08-23 Brown Michael P Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer
JP2013512454A (en) * 2009-12-01 2013-04-11 メディミューン，エルエルシー Improved methods and compositions for detecting and treating cancers expressing CEA
WO2015143029A1 (en) * 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
US20190125852A1 (en) * 2016-06-03 2019-05-02 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045444A1 (en) * 1997-04-10 1998-10-15 The Regents Of The University Of California Vaccines with enhanced intracellular processing
WO2000014257A1 (en) * 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045444A1 (en) * 1997-04-10 1998-10-15 The Regents Of The University Of California Vaccines with enhanced intracellular processing
WO2000014257A1 (en) * 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANO M ET AL: "Induction of SIV-specific immune responses by using recombinant sendai viral vector", CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, XX, XX, PAGE(S) 1, XP002212654 *
LUBAROFF D M ET AL, THE JOURNAL OF UROLOGY, vol. 159, no. 5, 31 May 1998 (1998-05-31), pages 9, XP009002633 *

Also Published As

Publication number Publication date
WO2002040059A2 (en) 2002-05-23
AU2002239441A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
BR9608615A (en) Nucleic acid respiratory syncytial virus vaccines
EP1246644A4 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
EP0256092A4 (en) Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same.
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
PL346299A1 (en) Method of dna vaccination
ATE314095T1 (en) VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
WO1999044636A3 (en) Il-12 enhancement of immune responses to t-independent antigens
AUPN015794A0 (en) Variants of human papilloma virus antigens
WO1999029341A3 (en) Methods for enhancement of protective immume responses employing leishmania polypeptides
WO2002036141A3 (en) Method of enhancing lymphocyte-mediated immune responses
NO960309L (en) Agonists and antagonists of human interleukin-10
EP0658623A3 (en) Attenuated herpesviruses, herpesviruses which include foreign DNA encoding an amino acid sequence and vaccines containing same.
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
AU4559300A (en) Use of phyllanthus for targeted stimulation of the immune system
WO2002040059A3 (en) Methods and compositions for inducing cell-mediated immune responses
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
CA2272407A1 (en) Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
EP0712926A3 (en)
WO1999012951A8 (en) Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
WO2001079276A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
WO1999024077A3 (en) Compositions and methods for targeted delivery of biologically-active factors
WO2003018606A3 (en) Casein derived peptides and uses thereof in therapy
BR9815496A (en) Nucleic acid vaccines that code for respiratory syncytial virus protein
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP